Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection

Next Previous
Trial Profile

BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efavirenz (Primary) ; Abacavir; Didanosine; Emtricitabine; Lamivudine; Lamivudine/zidovudine; Nucleoside reverse transcriptase inhibitors; Stavudine; Tenofovir; Zidovudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms BREATHER; PENTA-16

Most Recent Events

  • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
  • 16 Jul 2013 Planned End Date changed from 30 Sep 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
  • 16 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top